This article is more than 5 years old. Information may no longer be current.

Topical cyclosporine shows best results for treating mild dry eye disease, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Topical cyclosporine appears to show benefit for patients with mild, moderate and severe dry eye disease who are unresponsive to artificial tears, a prospective study suggests.

Henry D. Perry, MD, and colleagues evaluated the use of Restasis (topical cyclosporine 0.05%, Allergan) in 62 patients with mild dry eye disease, 69 patients with moderate disease and 27 patients with severe disease.

Follow-up ranged from 3 to 16 months.

The investigators observed improvement in 46 patients (74.1%) with mild dry eye disease, 50 patients with moderate disease (72.4%) and 18 patients with severe disease (66.7%), for an overall improvement of 72.1%.

"The increased benefits of treatment in the mild group suggest that early treatment of dry eye disease may yield the best results," the authors said in the August issue of Archives of Ophthalmology.